Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $39.32 Average Price Target from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average rating of “Hold” from the thirty analysts that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $39.32.

A number of research analysts have commented on the stock. Piper Sandler increased their price target on shares of Sarepta Therapeutics to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, July 29th. The Goldman Sachs Group increased their price target on shares of Sarepta Therapeutics to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. BMO Capital Markets upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research report on Monday, September 22nd. Mizuho reaffirmed a “neutral” rating and issued a $14.00 target price (down from $40.00) on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Oppenheimer upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $30.00 to $37.00 in a report on Tuesday, July 29th.

Sarepta Therapeutics Stock Up 1.3%

Shares of NASDAQ SRPT opened at $22.64 on Friday. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $138.81. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The firm’s 50 day simple moving average is $18.39 and its two-hundred day simple moving average is $32.22. The stock has a market capitalization of $2.21 billion, a P/E ratio of -26.02 and a beta of 0.51.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. During the same period last year, the business earned $0.07 earnings per share. The business’s quarterly revenue was up 68.4% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Large investors have recently modified their holdings of the business. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the 1st quarter valued at about $30,000. Center for Financial Planning Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $31,000. Ancora Advisors LLC increased its stake in shares of Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the period. Banque Transatlantique SA bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $44,000. Finally, Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics in the first quarter worth $45,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.